Why that word, real?

Real

Real is a demanding word. It can sound reassuring before anyone has said what the reassurance rests on. With Real TRT, I wanted to follow the testosterone question far enough for that word to become awkward: a measurable response, a different population, a later observation, an outcome someone actually values.

Kisspeptin gives the question somewhere concrete to go. The early study in healthy men reported hormonal activity, including a testosterone rise. The repeated-exposure experiment in women with hypothalamic amenorrhea found a fading LH response. They investigate different populations and outcomes; together they place the follow-up at the centre of my curiosity.

I began by being impressed that the signal could be stimulated. I now give equal attention to the conditions under which a response persists, weakens or fails to appear. That is a change in emphasis, and it leaves plenty of room for enthusiasm about a good experiment.

An editorial project

Real TRT is the name of these pages, not a clinic or a treatment business. My subject here is published research; there is no prescribing, medicine sales, dispensing or arrangement of care here. Nothing on the site is medical advice.

The subject is deliberately specific: kisspeptin and the questions raised by its reproductive and sexual-desire research. This is no comprehensive account of testosterone treatment. A person deciding about care needs an assessment of their own circumstances, which a collection of essays cannot provide.

My favourite experiments make the original question less comfortable. The participants whose kisspeptin response failed to appear expose a gap in any simple account of the healthy-men response: the disagreement asks for an explanation. The sexual-desire trial opens another promising question with outcomes of its own.

My judgement can change when a better experiment arrives. For now, this subject seems worth the time precisely because its genuinely interesting findings leave consequential work to do.